Nicotinamide Riboside Combo Improves Hepatic Profiles in NAFLD

By August West, Contributing Writer

Supplementation with fixed combination of nicotinamide riboside, L-carnitine, L-serine, and N-acetyl cysteine resulted in improvement of myriad biomarkers of NAFLD (Image: Zeybel M, et al. Mol Syst Biol. 2021)

Daily supplementation with a fixed dose combination of nicotinamide riboside, L-carnitine, L-serine, and N-acetyl cysteine significantly reduced liver fat, quelled oxidative stress, and improved liver enzyme profiles in a cohort of 31 patients with non-alcoholic fatty liver disease (NAFLD).

Defined as hepatic fat accumulation of 5% or more, unrelated to alcohol consumption or other liver diseases, NAFLD affects roughly one in four adults according to recent estimates. Incidence is on the rise, driven in part by the close association of NAFLD with insulin resistance, diabetes, and obesity, all of which are increasing globally.

“Current management strategies, including lifestyle modification, increased physical activity, and dietary intervention, have limited adherence and minimal prolonged success,” wrote Mujdat Zeybel, of the NIHR Nottingham Biomedical Research Center, UK, and lead author of the new study.

Improving Clinical Outcomes with Paraprobiotics

Written by Erik Goldman

VIEW WEBINAR

Paraprobiotics could be just what your patients need for a better life. Pre- and probiotics have become mainstream solutions for improved overall wellbeing, but research has revealed that paraprobiotics–heat-killed probiotic strains–can also have very specific benefits. Paraprobiotics also deliver the added advantage of a longer shelf-life without the need for refrigeration.

In this free webinar, Danielle Citrolo, PharmD, and Shintaro Ichikawa, PhD, will discuss how paraprobiotics will benefit your patients. They will introduce you to IMMUSE and EYEMUSE, two branded forms of clinically studied strains that help to bolster immune function and vision by stimulating immune cells within the gut and the retina. IMMUSE is currently supported by eleven human trials and EYEMUSE is supported by two studies.

In this webinar, you will:

Gain an understanding of what are paraprobiotics, and why they could be a good alternative to probiotic strains in your practice.
Learn the importance of the immune system and its role in overall health.
Understand the ability of paraprobiotics to influence the immune system for improved health outcomes.
Learn about the published clinical research behind the unique paraprobiotic strains used for IMMUSE and EYEMUSE.